|
KMID : 0869120180200020055
|
|
기초간호자연과학회지
2018 Volume.20 No. 2 p.55 ~ p.66
|
|
|
Current Pharmacogenetic Approach for Oxaliplatin-induced Peripheral Neuropathy among Patients with Colorectal Cancer: A Systematic Review
|
|
Ahn Soo-Jung
Choi So-Young
Jung Hye-Jeong
Chu Sang-Hui
|
|
|
Abstract
|
|
|
Purpose: Peripheral neuropathy is common among colorectal cancer (CRC) patients who undergo oxaliplatin-based (OXL) chemo- therapy. A pharmacogenetic approach can be used to identify patients at high-risk of developing severe neuropathy. This type of ap- proach can also help clinicians determine the best treatment option and prevent severe neurotoxicity. The purpose of this study is to investigate the evidence of pharmacogenetic markers for OXL-induced peripheral neuropathy (OXIPN) in patients with CRC.
Methods: A systematic literature search was conducted using the following databases up to December 2017: Pubmed, EMBASE, and CI- NAHL. We reviewed the genetic risk factors for OXIPN in observational studies and randomized controlled clinical trials (RCTs). All pro- cesses were performed independently by two reviewers.
Results: Sixteen studies published in English between 2006 and 2017 were included in this review. A genome-wide association approach was used in one study and various candidate genes were tested, based on their functions (e.g., DNA damage or repair, ion channels, anti-oxidants, and nerve growth etc.). The genes associated with inci- dence or severity of OXIPN were ABCG2, GSTP1, XRCC1, TAC1, and ERCC1.
Conclusion: This study highlighted the need and the im- portance of conducting pharmacogenetic studies to generate evidence of personalized OXIPN symptoms management. Additional studies are warranted to accelerate the tailored interventions used for OXIPN in patients with CRC (NRF-2014R1A1A3054386).
|
|
|
KEYWORD
|
|
|
Oxaliplatin, Peripheralneuropathy, Pharmacogenetics, Colorectalcancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|